Aetion’s Post

ICON's Tim Clark has co-authored a peer-reviewed article on innovative approaches to dose-finding in early-phase oncology trials. With the advent of molecular targeted therapies, traditional methods like the 3+3 design may no longer be optimal. This paper explores Bayesian model-assisted designs and how they perform in real-world scenarios. Read the article to learn more: https://ow.ly/gYq750T9E4K #ClinicalTrials #OncologyResearch

Register with the link below for the upcoming webinar “The New Era of Project Optimus: Implications for Oncology Development Strategy” at 1 p.m. (Eastern), 25 September. Our experts will be discussing tangible examples and case studies of how drug development has played out in the Project Optimus era, uncovering lessons learned, best practices, and exploring the changing regulatory landscape. You won’t want to miss it! https://lnkd.in/gzGhHpMv... #Webinar #Oncology #ProjectOptimus

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/etyFrYKW #ParexelBiotech #ResearchSites #Oncology #NovelInsights

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/eThSTMGE #ParexelBiotech #ResearchSites #Oncology #NovelInsights

In two weeks, our team Ashley Sample, PhD, Markus Walz, and Taylor Carlsen, MD, MBA will head to Chicago to attend The American Society of Clinical Oncology Meeting. This Annual meeting will explore state-of-the-art research, treatments, and visionary insights. We are looking forward to sharing key insights from this meeting. Let us know what you would be interested in learning about from this meeting in the comments! #MagnoliaInnovation #ASCO24 #oncology #marketresearch #education

How do we position regional and community sites for success and mitigate risks for sponsors? In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/eWRvBqiN #ParexelBiotech #ResearchSites #Oncology #NovelInsights

Delays in #oncology research can have dire consequences – participant lives could be at stake.  Therefore, early phase oncology sponsors need to keep their study timelines on track, and a fully integrated CDMS/EDC solution could be the key. Read our latest blog to learn how a CDMS/EDC system that integrates with eConsent, eCOA/ePRO, and RTSM can help your oncology trial stay on track. https://bit.ly/3V0T0WL #ClinicalTrials #ClinicalDataManagement #EDC #ePRO #eConsent #RTSM #PatientCentricity

Here’s a sneak peek at the first installment of our upcoming video series, “Re-inventing the ‘How’” featuring N-Power’s CEO Mark Lee, MD, PhD and Michael Seiden MD, PhD, N-Power advisor and former President of the US Oncology Network, as they highlight the need for a new integrated model of clinical research and routine care in community oncology to accelerate drug development. Learn more about N-Power: https://lnkd.in/gJESRx3g #oncologyresearch #cancerresearch #realworlddata #HealthcareAI #oncologydrugdevelopment #RWE #Oncology

Really enjoyed my fireside chat with Michael Seiden MD, PhD, former President of the US Oncology Network, where we discussed the need for a new, holistic approach to make clinical research truly accessible for more oncologists and more cancer patients than ever before. Check out this sneak peek preview of our conversation as part of N-Power Medicine, Inc.'s new video series, "Reinventing the How" -- full episode coming next week!

The desire to capture the promise of AI in healthcare is accelerating the need to integrate technology with patient safety. We at N-Power Medicine, Inc. are aligned with the healthcare providers that first we have the duty to do no harm. Therefore, we are “Re-inventing the How” as we know data is only as good as its source – our advisor Michael Seiden MD, PhD, in conversation with our CEO Mark Lee so clearly articulated that “we need comprehensive, well-articulated datasets that look at the entire cancer journey.” With an eye on that N-Power Medicine, Inc. is creating a research-ready integrated platform to generate important insights for clinical research and accelerate drug development. #AI #Cancer #Research #ClinicalTrials